Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds

Rhea-AI Summary

A new Quest Diagnostics (DGX) report reveals concerning trends in cancer care, with 76% of oncologists reporting increased advanced cancer cases. Among these, 75% attribute this rise to screening barriers. The report highlights significant challenges in detecting cancer recurrence, with 79% of oncologists encountering cases where recurrence was missed in earlier stages. Key findings show that 68% of cases were missed due to delayed follow-up care, while 50% cite limitations in current imaging tests. The study emphasizes the potential of circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing, with 94% of oncologists believing it could reduce diagnosis delays. Quest's Haystack MRD™ test has shown promising results, detecting treatment response 1.4 months faster than traditional methods. However, broader adoption faces barriers including insurance coverage and the need for more clinical evidence.

Positive

• 94% of oncologists believe ctDNA MRD testing could reduce cancer recurrence diagnosis delays
• Quest's Haystack MRD test showed faster detection (1.4 months) compared to traditional methods (6.1 months)
• 88% of oncologists support incorporating MRD testing into standard cancer care
• 71% of oncologists prefer working with a single laboratory for comprehensive cancer testing

Negative

• 76% of oncologists report seeing more advanced-stage cancers
• 79% of oncologists report cases where cancer recurrence was missed in earlier stages
• 89% of oncologists express frustration with insurance reimbursement models not keeping pace with innovations
• Current imaging tests fail to detect recurrence early enough in 50% of missed cases

Insights

Oncology Expert

Quest's Haystack MRD blood test shows strong clinical potential as oncologists express frustration with current cancer recurrence detection methods.

The findings from Quest Diagnostics' oncologist survey reveal a troubling trend in cancer care that deserves serious attention. The report that 76% of oncologists are seeing more advanced cancers, with 75% attributing this to screening barriers, highlights a critical gap in our healthcare infrastructure.

What's particularly concerning from a clinical perspective is that 79% of oncologists report seeing patients whose cancer recurrence was missed at earlier stages. The primary culprits? Patient non-adherence to follow-up appointments (68%) and—crucially—50% cite imaging tests failing to detect recurrence early enough. This underscores a significant limitation in our current monitoring approaches.

The ctDNA minimal residual disease (MRD) testing technology represents a potentially transformative approach to cancer monitoring. The 94% of oncologists who believe these tests could reduce diagnosis delays in recurrence is remarkable consensus in a field often divided on new technologies. The Memorial Sloan Kettering study published in NEJM showing Haystack MRD's ability to identify complete response to immunotherapy in just 1.4 months (versus 6.1 months for traditional methods) demonstrates meaningful clinical advantage in response time assessment.

However, we must address the implementation barriers oncologists identified: 61% want more clinical evidence, 64% seek inclusion in clinical guidelines, and 56% need expanded insurance coverage. These are solvable problems, but require coordinated effort across the healthcare ecosystem.

With cancer cases expected to exceed 2 million in 2025 and survivors projected to reach 26 million by 2040, we need better surveillance tools. The 20-40% recurrence rate for common solid tumors makes this an urgent clinical need rather than a luxury.

Healthcare Financial Analyst

Quest's Haystack MRD test shows strong market potential with 88% of oncologists supporting its incorporation into standard care protocols.

Quest Diagnostics' report reveals significant market opportunity in the cancer recurrence monitoring space. The company has strategically positioned itself with the Haystack MRD™ test launch earlier this year, addressing what 89% of surveyed oncologists identify as a critical need for earlier cancer recurrence detection.

The survey data points to strong physician demand for better diagnostic tools, with 88% of oncologists agreeing MRD testing should become standard of care for cancer recurrence monitoring. This represents substantial revenue growth potential for Quest's diagnostic portfolio, particularly as cancer survivorship is projected to increase from 18.1 million in 2020 to 26 million by 2040.

Quest's competitive positioning is enhanced by the April 2025 Memorial Sloan Kettering study published in NEJM, which validated the Haystack MRD test as a 77% faster assessment tool than traditional methods (1.4 months versus 6.1 months). This performance advantage creates compelling value proposition for adoption.

A key finding with revenue implications is that 71% of oncologists prefer working with a single laboratory offering comprehensive cancer testing rather than multiple specialized labs. This preference for integrated testing solutions strongly favors Quest's broad-spectrum approach and could drive increased market share.

However, reimbursement remains a challenge, with 89% of oncologists expressing frustration that insurance models aren't keeping pace with diagnostic innovations. Quest will need to navigate payer negotiations effectively to maximize the commercial potential of their MRD testing platform. The 56% of oncologists citing insurance coverage as a barrier to adoption highlights this as a critical business focus area for Quest to address for successful market penetration.

• More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors that we don't understand yet"
  
  
• Missed/delayed follow-up care or monitoring appointments by patients (68%) and imaging tests not detecting recurrence early enough (50%) are among the primary reasons cancer recurrence is typically missed, according to oncologists whose patients' cancer recurrence was missed in an earlier stage
  
  
• 94% of oncologists say circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing could reduce diagnosis delays in cancer recurrence but cite hurdles to wide adoption

SECAUCUS, N.J., May 13, 2025 /PRNewswire/ -- Oncologists feel they are seeing more and more patients with advanced cancers, say screening barriers are the leading reason why, and worry that current tests may not catch cancer recurrence early enough, according to a new report, "The Cancer Paradox: Oncologists' Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring."

To access the full report, click here.

Based on a survey conducted by The Harris Poll on behalf of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, the new report highlights perspectives of medical and surgical oncologists about the prevalence of advanced-stage cancers, the anxieties and barriers they believe patients face in accessing care, and the need for better post-treatment tools. It also provides novel insights into the perceptions of oncologists of an emerging area of clinical testing: ctDNA minimal residual disease (MRD) blood tests to aid in monitoring for residual or recurring cancer in patients treated for solid tumors. Quest Diagnostics launched its first ctDNA MRD test, Haystack MRD™, earlier this year.

"We call it the cancer paradox: As medical advances improve longevity, more patients than ever face the looming risk of cancer recurrence — and the anxieties and challenges that go with it," said board-certified oncologist Yuri A. Fesko, M.D., senior vice president and chief medical officer, Quest Diagnostics. "Our new survey reveals the unique challenges oncologists face at a time when an unprecedented number of Americans are alive following cancer treatment but for whom the specter of recurrence remains a real concern for both the patient and the provider."

Despite new treatments, new cancer cases in the U.S. are expected to cross the 2 million mark in 2025 for the second year in a row and the number of survivors is expected to rise from 18.1 million in 2020 to 26 million by 2040.^{i, ii} Cancer recurrence varies by type and stage, but as many as 20-40% of the four most common solid tumor cancers — breast, colorectal, lung and prostate — recur after surgery.ⁱⁱⁱ

Key survey findings:

• 76% of oncologists feel they are seeing more advanced-stage cancers, and of these, 75% believe that screening barriers are the leading cause, followed by rise in aging population (48%) and lifestyle factors (43%). Roughly one in three (32%) cite "factors that we don't understand yet" behind the perceived increase.
  
  
• While 89% of oncologists believe identifying cancer recurrence at the earliest possible stage can improve outcomes, roughly 8 in 10 oncologists (79%) report seeing patients whose cancer recurrence was missed in an earlier stage. Of these oncologists, 68% claim missing, skipping and/or delaying follow-up care and monitoring appointments is the most common reason cancer recurrence is typically missed.
  
  
• 87% of oncologists claim anxiety/worry is among the most challenging aspects of cancer care for patients, versus 53% who cite treatment side effects as among the most challenging.
  
  
• Nine in 10 oncologists (89%) express frustration that insurance reimbursement models are unable to keep up with the latest tech innovations in cancer care, screening, and diagnostics.

Oncologists Value ctDNA MRD Tests but Cite Barriers to Adoption
Oncologists have traditionally monitored for residual or recurring cancer using a range of expensive or invasive technologies, including positron emission tomography (PET) scans, magnetic resonance imaging (MRI), and tissue biopsies, as well as more accessible but typically nonspecific lab tests.

Yet, oncologists expressed concerns about these traditional methods. Among oncologists whose patients' recurrence was missed in an earlier stage, half (50%) said imaging tests not detecting recurrence early enough was among the primary reasons for why cancer recurrence is typically missed. By comparison, nearly all oncologists (96%) said MRD testing has the potential to identify cancer recurrence earlier than other current methods, with 89% saying test sensitivity to accurately detect residual disease/recurrence as early as possible is one of the most important features of MRD tests.

"We were struck by how many oncologists cited the limitations of imaging in detecting cancer recurrence early," said Dan Edelstein, vice president, general manager and co-founder of Haystack Oncology, a Quest Diagnostics company. "There's a clear desire for more sensitive tools, and oncologists increasingly see high-performance ctDNA blood tests as a promising solution for earlier detection of residual or recurrent cancer."

Nearly nine in 10 oncologists (88%) agree that MRD testing should be incorporated into the standard of care for cancer-recurrence follow-up monitoring. However, over half say they would be more likely to start, continue, or restart recommending MRD tests if they had more clinical evidence to support effectiveness (61%), were in clinical guidelines (64%), and have expanded insurance or reimbursement coverage (56%).

 A study by researchers at Memorial Sloan Kettering Cancer Study published in The New England Journal of Medicine (NEJM) in April 2025 found that the Haystack MRD test was a "reliable liquid biopsy surrogate" for tissue biopsy results in assessing efficacy of an immunotherapy that successfully treated 80% of patients with several types of solid tumors without surgery, radiation or chemotherapy. The median time for the Haystack MRD test to identify complete response to the immunotherapy was 1.4 months, faster than PET imaging or endoscopy (both 6.1 months). 

The survey also polled oncologists on their preferences for accessing laboratory tests: 71% said they prefer to work with a single laboratory with a broad selection of cancer tests spanning the care continuum versus several labs that each focus on one portion of the patient's journey.

Study Methodology
On behalf of Quest, The Harris Poll surveyed oncologists (174 medical oncologists and 76 surgical oncologists) between August 6 and September 4, 2024, to gather insights into how they perceived and manage the challenges of cancer recurrence. Read the study here for complete methodology.

About Haystack MRD™
Finding the needle of cancer with a simple blood draw: That's Haystack MRD, a highly sensitive and specific liquid biopsy test designed by cancer genomic pioneers and liquid biopsy experts to uncover the lowest level of circulating tumor DNA (ctDNA)—tiny bits of DNA in the bloodstream that originate from tumor cancer cells that can signify residual, recurrent, or resistant disease. Used in multiple clinical trials and research studies with top institutions in the U.S., Canada, and Australia, and by oncologists at over 75 top cancer and academic centers and health systems, Haystack MRD is now available for clinical use as part of the leading oncology testing portfolio of Quest Diagnostics. For more information, visit HaystackMRD.com. 

About Quest Diagnostics 
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

i Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):7–33. doi:10.3322/caac.21871.
ⁱⁱ Tonorezos E, Devasia T, Mariotto AB, Mollica MA, Gallicchio L, Green P, Doose M, Brick R, Streck B, Reed C, de Moor JS, Prevalence of Cancer Survivors in the United States, JNCI: Journal of the National Cancer Institute, 2024; https://doi.org/10.1093/jnci/djae135
ⁱⁱⁱ Aliperti LA, Predina JD, Vachani A, Singhal S. Local and systemic recurrence is the Achilles heel of cancer surgery. Ann Surg Oncol. 2011 Mar;18(3):603-7. doi: 10.1245/s10434-010-1442-0. PMID: 21161729; PMCID: PMC11156256. Local and Systemic Recurrence is the Achilles Heel of Cancer Surgery - PMC

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncologists-report-seeing-more-advanced-cancers-and-say-current-tests-are-not-catching-cancer-recurrence-early-enough-new-quest-diagnostics-report-finds-302452910.html

SOURCE Quest Diagnostics

FAQ

What percentage of DGX oncologists report seeing more advanced cancers in 2025?

76% of oncologists surveyed report seeing more advanced-stage cancers, with 75% citing screening barriers as the primary cause.

How effective is Quest Diagnostics' Haystack MRD test compared to traditional methods?

The Haystack MRD test identified complete response to immunotherapy in 1.4 months, compared to 6.1 months for PET imaging or endoscopy.

What are the main barriers to cancer recurrence detection according to Quest Diagnostics' 2025 report?

The main barriers are missed/delayed follow-up care (68% of cases) and imaging tests not detecting recurrence early enough (50% of cases).

What percentage of oncologists support adding MRD testing to standard cancer care?

88% of oncologists agree that MRD testing should be incorporated into the standard of care for cancer-recurrence follow-up monitoring.

What are the main challenges for widespread adoption of ctDNA MRD testing according to Quest's survey?

Key challenges include the need for more clinical evidence (61%), inclusion in clinical guidelines (64%), and expanded insurance/reimbursement coverage (56%).